An immune system disorder that occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues. Activated donor T cells damage host epithelial c...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The documentation surrounding graft versus host disease is limited primarily due to its rarity, affecting fewer than 10 individuals per 100,000. This low prevalence restricts the scope of systematic clinical studies and comprehensive phenotypic characterization. Additionally, the complexity of the immune response involved in GVHD contributes to the challenges in defining clinical features and treatment responses.
To navigate graft versus host disease effectively, consider consulting with a hematologist or oncologist who specializes in transplant-related complications. They can provide insights into the latest treatment options and clinical trials. You may also explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. Participating in clinical trials could also provide access to cutting-edge therapies and contribute to the understanding of this condition.
There are currently 358 active clinical trials investigating various aspects of graft versus host disease. Notable FDA-approved orphan drugs for GVHD include abatacept, belumosudil, and ruxolitinib. In addition, several drugs are designated for development, including anti-CD3 monoclonal antibodies and interleukin-1 receptor antagonists. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=graft%20versus%20host%20disease. This active research landscape offers hope for improved management strategies.
Actionable guidance for navigating care for graft versus host disease
To navigate graft versus host disease effectively, consider consulting with a hematologist or oncologist who specializes in transplant-related complications. They can provide insights into the latest treatment options and clinical trials. You may also explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. Participating in clinical trials could also provide access to cutting-edge therapies and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 54 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.